Olaparib
- Generic Name
- Olaparib
- Brand Names
- Lynparza
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23FN4O3
- CAS Number
- 763113-22-0
- Unique Ingredient Identifier
- WOH1JD9AR8
- Background
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...
- Indication
Ovarian cancer
Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
- Associated Therapies
- Maintenance therapy
Chemo-free BRCA-targeted Neoadjuvant Strategy
- Conditions
- Interventions
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT05203445
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2023-02-24
- Target Recruit Count
- 40
- Registration Number
- NCT05201612
- Locations
- 🇪🇸
Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Aragon, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Comunitat Valenciana, Spain
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
- Conditions
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 136
- Registration Number
- NCT05174832
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT05171816
- Locations
- 🇨🇳
Research Site, Zhejiang, China
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Kosei Hasegawa, MD, PhD
- Target Recruit Count
- 35
- Registration Number
- NCT05158062
- Locations
- 🇯🇵
Saitama Medical Uiversity International Medical Center, Hidaka, Saitama, Japan
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT05156268
- Locations
- 🇺🇸
Maria Rubinstein, Rockville Centre, New York, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT05128734
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 20
- Registration Number
- NCT05093231
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 160
- Registration Number
- NCT05078671
- Locations
- 🇳🇱
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
🇳🇱Amsterdam Universitair Medische Centra, Amsterdam, Netherlands
🇳🇱Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.